Reilly Financial Advisors LLC boosted its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 14.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 790 shares of the medical instruments supplier’s stock after buying an additional 101 shares during the period. Reilly Financial Advisors LLC’s holdings in Becton Dickinson and were worth $178,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of BDX. Morgan Stanley increased its holdings in shares of Becton Dickinson and by 133.0% in the 3rd quarter. Morgan Stanley now owns 2,771,269 shares of the medical instruments supplier’s stock worth $723,303,000 after purchasing an additional 1,581,829 shares in the last quarter. FMR LLC lifted its position in Becton Dickinson and by 8.0% during the third quarter. FMR LLC now owns 17,354,031 shares of the medical instruments supplier’s stock valued at $4,529,401,000 after purchasing an additional 1,286,579 shares in the last quarter. Cornerstone Wealth Management LLC lifted its position in Becton Dickinson and by 233.6% during the third quarter. Cornerstone Wealth Management LLC now owns 647,786 shares of the medical instruments supplier’s stock valued at $3,286,000 after purchasing an additional 453,623 shares in the last quarter. Vanguard Group Inc lifted its position in Becton Dickinson and by 1.3% during the third quarter. Vanguard Group Inc now owns 21,666,262 shares of the medical instruments supplier’s stock valued at $5,654,895,000 after purchasing an additional 283,433 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in Becton Dickinson and by 1.3% during the 3rd quarter. Vanguard Group Inc. now owns 21,666,262 shares of the medical instruments supplier’s stock worth $5,654,895,000 after buying an additional 283,433 shares in the last quarter. 86.28% of the stock is owned by institutional investors.
BDX has been the subject of several recent research reports. TheStreet raised Becton Dickinson and from a “c+” rating to an “a” rating in a report on Tuesday, February 5th. Piper Jaffray Companies boosted their price objective on Becton Dickinson and to $274.00 and gave the stock an “overweight” rating in a report on Tuesday, February 5th. Zacks Investment Research raised Becton Dickinson and from a “hold” rating to a “buy” rating and set a $243.00 price target for the company in a research note on Tuesday, January 8th. Morgan Stanley lowered their price target on Becton Dickinson and from $265.00 to $240.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 2nd. Finally, Citigroup lowered their price target on Becton Dickinson and from $279.00 to $256.00 and set a “buy” rating for the company in a research note on Wednesday, January 2nd. Six equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $253.17.
BDX opened at $245.05 on Thursday. Becton Dickinson and Co has a 1-year low of $208.62 and a 1-year high of $265.87. The company has a current ratio of 0.97, a quick ratio of 0.62 and a debt-to-equity ratio of 0.83. The firm has a market capitalization of $65.45 billion, a P/E ratio of 22.26, a price-to-earnings-growth ratio of 1.70 and a beta of 1.23.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Tuesday, February 5th. The medical instruments supplier reported $2.70 earnings per share for the quarter, beating analysts’ consensus estimates of $2.58 by $0.12. The business had revenue of $4.16 billion for the quarter, compared to analysts’ expectations of $4.10 billion. Becton Dickinson and had a return on equity of 14.65% and a net margin of 5.69%. The firm’s revenue for the quarter was up 35.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.48 EPS. As a group, equities analysts expect that Becton Dickinson and Co will post 12.1 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 29th. Shareholders of record on Friday, March 8th will be given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 1.26%. The ex-dividend date of this dividend is Thursday, March 7th. Becton Dickinson and’s payout ratio is 27.97%.
In related news, EVP James W. Borzi sold 5,887 shares of the firm’s stock in a transaction dated Friday, November 30th. The stock was sold at an average price of $252.37, for a total value of $1,485,702.19. Following the sale, the executive vice president now directly owns 6,013 shares of the company’s stock, valued at $1,517,500.81. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Charles R. Bodner sold 2,080 shares of the firm’s stock in a transaction dated Friday, November 16th. The shares were sold at an average price of $245.83, for a total value of $511,326.40. Following the completion of the sale, the senior vice president now directly owns 4,497 shares in the company, valued at $1,105,497.51. The disclosure for this sale can be found here. Insiders have sold a total of 13,210 shares of company stock worth $3,275,587 in the last quarter. Company insiders own 0.12% of the company’s stock.
WARNING: “Reilly Financial Advisors LLC Purchases 101 Shares of Becton Dickinson and Co (BDX)” was first reported by Highlight Press and is owned by of Highlight Press. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://highlightpress.com/2019/02/14/reilly-financial-advisors-llc-has-178000-stake-in-becton-dickinson-and-co-bdx.html.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.